ABSTRACT
Almost 90% of neuromuscular diseases (NMDs) are classified as rare diseases, defined as conditions affecting less than 5 individuals in 10.000 (0.05%). Their rarity and diversity pose specific challenges for healthcare and research. Epidemiological data on NMDs are often lacking and incomplete. The COVID-19 pandemic has further highlighted the management difficulties of NMDs patients and the necessity to continue the program of implementation of standard of care. This article summarizes the Italian experience during pandemic.
Subject(s)
COVID-19 , Frailty , Neuromuscular Diseases , COVID-19/epidemiology , Humans , Neuromuscular Diseases/epidemiology , Pandemics , SARS-CoV-2ABSTRACT
The above article was published online with inverted given and family names. The correct presentation has been corrected above.
ABSTRACT
Quarantine is a well-known risk factor for psychological and psychiatric disturbances. We evaluated burden of migraine during lockdown due to COVID 19 pandemia. Forty-nine subjects followed in our headache clinic for migraine were evaluated for migraine burden by means of global assessment of migraine severity (GAMS) and visual analogue scale (VAS) by phone interview. Moreover, depression and anxiety were quantified by Beck depression inventory (BDI) and Zung Self-Rating Anxiety Scale (SAS). We evaluated changes in the value of migraine score from the 2 months immediately before lockdown (from January 1 to March 9) to the 2 months of quarantine (from March 10 to May 3). Value of GAMS was 5.61 ± 0.76 before and 4.16 ± 1.46 during quarantine (p < .001). VAS was 7.49 ± 1.10 before and 5.47 ± 1.88 during quarantine (p < .001). We also found a time by depression level interaction, F(1,47) = 6.21, p = .016, F(1,47) = 14.52, p < .006, respectively, showing that subjects with lower level of depression had better course of migraine. In conclusion, we showed that, during quarantine due to COVID pandemia, subjects with migraine had fewer migraine attacks and lesser pain and show moderate level of depression, correlated to migraine burden.
Subject(s)
Coronavirus Infections , Migraine Disorders/epidemiology , Pandemics , Pneumonia, Viral , Quarantine/psychology , Adolescent , Adult , Aged , Betacoronavirus , COVID-19 , Cohort Studies , Depression/epidemiology , Depression/etiology , Female , Humans , Italy , Male , Middle Aged , Retrospective Studies , Risk Factors , SARS-CoV-2 , Surveys and Questionnaires , Young AdultSubject(s)
Betacoronavirus/drug effects , Coronavirus Infections/drug therapy , Guillain-Barre Syndrome/drug therapy , Immunoglobulins, Intravenous/therapeutic use , Pneumonia, Viral/drug therapy , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Guillain-Barre Syndrome/complications , Guillain-Barre Syndrome/virology , Humans , Immunization, Passive , Italy , Male , Middle Aged , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/diagnosis , SARS-CoV-2 , COVID-19 SerotherapyABSTRACT
Recently, some cases of Guillain Barré syndrome (GBS) and Miller Fisher (MF) have been reported, following COVID-19 infection1-2-3 . We report two different clinical manifestation of Covid-19 related GBS , one is a GBS/MF overlap syndrome, the other one an Acute Motor Sensory Axonal Neuropathy (AMSAN) with massive vegetative impairment, both highly responsive to intravenous immunoglobulins.